bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
210 hedge funds and large institutions have $3.8B invested in bluebird bio in 2015 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 18 closing their positions.
228% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 18
39% more call options, than puts
Call options by funds: $97.3M | Put options by funds: $70M
39% more capital invested
Capital invested by funds: $2.74B → $3.8B (+$1.06B)
24% more funds holding
Funds holding: 169 → 210 (+41)
4% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 68
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$131M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$63M |
| 3 |
O
OrbiMed
New York
|
+$56.1M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$55M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$111M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$31.1M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$23.2M |
| 4 |
DM
Deerfield Management
New York
|
-$22.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$17.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MFS
226
MSI Financial Services
Springfield,
Massachusetts
| – | -$73K | -61 | Closed |
|
|
QT
227
Quantbot Technologies
New York
| – | -$56K | -47 | Closed |
|
228
Credit Agricole
Montrouge Cedex,
France
| – | -$19K | -15 | Closed |
|
BLUE Hedge Fund Activity: Q1 2015 in Review
210 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2015, worth a combined $3.8B — up 39% from $2.74B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BLUE positions and 18 closed out — a net gain of 41 holders — while 71 added to existing stakes and 68 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $131M. The largest seller was Third Rock Ventures, exiting entirely with an estimated $111M sold.
- 210 institutional investors held bluebird bio (BLUE) as of Q1 2015, up from 169 in Q4 2014.
- Funds reported $3.8B of bluebird bio stock for Q1 2015, up 39% quarter-over-quarter.
- 59 funds opened new bluebird bio positions in Q1 2015 and 18 closed out, a net change of +41 holders.
- The largest bluebird bio buyer in Q1 2015 was Baillie Gifford & Co, an estimated $131M added.
- The largest bluebird bio seller in Q1 2015 was Third Rock Ventures, an estimated $111M sold.
Based on aggregated 13F filings for Q1 2015.